Pricing Log in Create free account
Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue
+51.9%
EPS
+73.9%
Free cash flow
−1,078.3%
Total debt
+4.04%

Quarter to September 2026, against a year earlier

132.13 2.33 +1.80%
Market cap
$6.8B
P/E
0.0×
Fwd P/E
−49.2×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Axsome Therapeutics, Inc. 10-Q filed Nov 2, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:31 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 10, 2026: no comparison — low extraction confidence